Bristol-Myers Squibb Co. (BMY) agreed to pay about $2.5 billion in cash to buy Inhibitex Inc. (INHX), the second maker of hepatitis C drugs to be acquired within two months as companies jockey for position in a developing $20 billion market.
Inhibitex, based in Alpharetta, Georgia, said it will recommend that its shareholders accept Bristol's offer of $26 per share, the companies said in a statement yesterday. That’s more than double its $9.87 closing price on Jan. 6.
The stock this morning is trading at $24.90 in the premarket.
The problem is that over the couple of weeks before the deal was announced, starting around the 15th of December, someone was buying the hell out of the January $10, $12.50 and $15 calls.
Needless to say these $10 calls are worth almost $15 each this morning, where they cost a couple of bucks or less. And with the stick trading under $10, and two weeks to expiry, had there been no inside information (that is, no deal) the calls would have likely been worth zero -- that is, very unlikely to have been worth anything.
You don't think someone might have been tipped off, do you?
Where We Are, Where We're Heading (2013) - The annual 2013 Ticker
The content on this site is provided without any warranty, express or implied. All opinions expressed on this site are those of the author and may contain errors or omissions.
NO MATERIAL HERE CONSTITUTES "INVESTMENT ADVICE" NOR IS IT A RECOMMENDATION TO BUY OR SELL ANY FINANCIAL INSTRUMENT, INCLUDING BUT NOT LIMITED TO STOCKS, OPTIONS, BONDS OR FUTURES.
The author may have a position in any company or security mentioned herein. Actions you undertake as a consequence of any analysis, opinion or advertisement on this site are your sole responsibility.
Looking for "The Best of Market Ticker"? Check out Ticker Classics.
Market charts, when present, used with permission of TD Ameritrade/ThinkOrSwim Inc. Neither TD Ameritrade or ThinkOrSwim have reviewed, approved or disapproved any content herein.
The Market Ticker content may be reproduced or excerpted online for non-commercial purposes provided full attribution is given and the original article source is linked to. Please contact Karl Denninger for reprint permission in other media or for commercial use.
Submissions or tips on matters of economic or political interest may be sent "over the transom" to The Editor at any time. To be considered for publication your submission must include full and correct contact information and be related to an economic or political matter of the day. All submissions become the property of The Market Ticker.